You are referring to the committee, I believe.
We certainly identified some shortcomings in this committee’s work, in the sense that it has no clear directives and usage criteria on which to base decisions about the medications included in the list of those that are covered. We also observed that there is no fixed timeline for implementing those decisions. We identified problems with the committee, but I believe that it is, in general, a good idea to have a committee with all the skills needed to examine medications and to make decisions of that kind.